Salidroside ameliorates pathological cardiac hypertrophy via TLR4‐TAK1 ‐dependent signaling
Phytotherapy Research · 2023-05 · 37 (5) · 1839-1849
DOI: 10.1002/ptr.7701 ↗At a glance
Journal article in Phytotherapy Research, published online on 2022-12-13. Written by Zhen Guo and 9 co-authors. Institution: Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China. Major MEDLINE topics: Aortic Valve Stenosis, Cardiomegaly, Toll-Like Receptor 4. Cited 10 times so far (Crossref); 47 references. Funded by: National Natural Science Foundation of China.
Abstract (original language)
Salidroside, a prominent active ingredient in traditional Chinese medicines, is garnering increased attention because of its unique pharmacological effects against ischemic heart disease via MAPK signaling, which plays a critical role in regulating the evolution of ventricular hypertrophy. However, the function of Salidroside on myocardial hypertrophy has not yet been elucidated. C57BL/6 mice were subjected to transverse aortic constriction (TAC), and treated with Salidroside (100 mg kg −1 day −1 ) by oral gavage for 3 weeks starting 1 week after surgery. Four weeks after TAC surgery, the mice were subjected to echocardiography and then sacrificed to harvest the hearts for analysis. For in vitro study, neonatal rat cardiomyocytes were used to validate the protective effects of Salidroside in response to Angiotensin II (Ang II, 1 μM) stimulation. Here, we proved that Salidroside dramatically inhibited hypertrophic reactions generated by pressure overload and isoproterenol (ISO) injection. Salidroside prevented the activation of the TAK1‐JNK/p38 axis. Salidroside pretreatment of TAK1‐inhibited cardiomyocytes shows no additional attenuation of Ang II‐induced cardiomyocytes hypertrophy and signaling pathway activation. The overexpression of constitutively active TAK1 removed the protective effects of Salidroside on myocardial hypertrophy. TAC‐induced increase of TLR4 protein expression was reduced considerably in the Salidroside treated mice. Transient transfection of small interfering RNA targeting TLR4 (siTLR4) in cardiomyocytes did not further decrease the activation of the TAK1/JNK‐p38 axis. In conclusion, Salidroside functioned as a TLR4 inhibitor and displayed anti‐hypertrophic action via the TAK1/JNK‐p38 pathway.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China.
- Hubei Key Laboratory of Metabolic and Chronic Diseases, Wuhan, People's Republic of China.
ORCID profiles: Qi-Zhu Tang
Funding
- National Natural Science Foundation of China
Cite
APA
Guo, Z., Liu, F. Y., Yang, D., Wang, M. Y., Li, C. F., Tang, N., Ma, S. Q., An, P., Yang, Z., & Tang, Q. Z. (2023). Salidroside ameliorates pathological cardiac hypertrophy via TLR4‐TAK1 ‐dependent signaling. Phytotherapy Research, 37(5), 1839-1849. https://doi.org/10.1002/ptr.7701
Vancouver
Guo Z, Liu FY, Yang D, Wang MY, Li CF, Tang N, et al. Salidroside ameliorates pathological cardiac hypertrophy via TLR4‐TAK1 ‐dependent signaling. Phytotherapy Research. 2023;37(5):1839-1849. doi:10.1002/ptr.7701
BibTeX
@article{Guo2023,
author = {Guo, Zhen and Liu, Fang-Yuan and Yang, Dan and Wang, Ming-Yu and Li, Chen-Fei and Tang, Nan and Ma, Shu-Qing and An, Peng and Yang, Zheng and Tang, Qi-Zhu},
title = {Salidroside ameliorates pathological cardiac hypertrophy via TLR4‐TAK1 ‐dependent signaling},
journal = {Phytotherapy Research},
year = {2023},
volume = {37},
number = {5},
pages = {1839--1849},
doi = {10.1002/ptr.7701}
}
EUVIMED